These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18446706)

  • 1. Better understanding of ADPKD results in potential new treatment options: ready for the cure?
    Meijer E; de Jong PE; Peters DJ; Gansevoort RT
    J Nephrol; 2008; 21(2):133-8. PubMed ID: 18446706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.
    Messchendorp AL; Casteleijn NF; Meijer E; Gansevoort RT
    Nephrol Dial Transplant; 2020 Aug; 35(8):1306-1316. PubMed ID: 31077332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.
    Devuyst O; Torres VE
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):459-70. PubMed ID: 23736843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
    Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ADPKD treatment: Tolvaptan and Octreotide].
    Galliani M; Chicca S; Vitaliano E; Moscaritolo E; Calvaruso L; Iorio F; Paone A
    G Ital Nefrol; 2019 Dec; 36(6):. PubMed ID: 31830392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].
    Cornec-Le Gall E; Le Meur Y
    Nephrol Ther; 2014 Nov; 10(6):433-40. PubMed ID: 25086476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on tolvaptan for autosomal dominant polycystic kidney disease.
    Poch E; Rodas L; Blasco M; Molina A; Quintana L
    Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].
    Perico N; Cortinovis M; Remuzzi G
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects.
    Chang MY; Ong AC
    Nephron Clin Pract; 2012; 120(1):c25-34; discussion c35. PubMed ID: 22205396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
    Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
    N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP; Kistler AD; Serra AL
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel treatments of autosomal dominant polycystic kidney disease.
    Mahnensmith RL
    Clin J Am Soc Nephrol; 2014 May; 9(5):831-6. PubMed ID: 24721886
    [No Abstract]   [Full Text] [Related]  

  • 14. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New options in the treatment of autosomal dominant polycystic kidney disease.
    Kazancioglu R; Gursu M
    Ren Fail; 2015 May; 37(4):535-41. PubMed ID: 25682970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature.
    Capuano I; Buonanno P; Riccio E; Rizzo M; Pisani A
    Clin Nephrol; 2022 Mar; 97(3):131-140. PubMed ID: 34846296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Modern treatment of autosomal dominant polycystic kidney disease].
    Wołyniec W; Jankowska MM; Rutkowski B
    Pol Merkur Lekarski; 2008 Oct; 25(148):374-9. PubMed ID: 19145940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
    N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic interventions for autosomal dominant polycystic kidney disease.
    Edelstein CL
    Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.
    Serra AL; Kistler AD; Poster D; Struker M; Wüthrich RP; Weishaupt D; Tschirch F
    BMC Nephrol; 2007 Sep; 8():13. PubMed ID: 17868472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.